Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
July 26, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for July 14, 2005 Subscribe to this News Feed     Subscribe to this Podcast Feed  
 

With Reports of Death, FDA Warns Multiple Sclerosis (MS) Patients Against Pharmaceutical Drug Tysabri

Campaign launched to rally Multiple Sclerosis patients in potential class action lawsuit against the manufacturer of pharmaceutical drugs Tysabri and Avonex.

Wilmington, NC (PRWEB) July 14, 2005 -- Greg Jones & Associates, a North Carolina-based law firm, in association with www.lawyersandsettlements.com, launches a marketing campaign to increase awareness of the Multiple Sclerosis drug, Tysabri. Makers of Tysabri, Biogen Idec Inc. and Elan Pharmaceuticals Inc., have recently taken the drug off the market and sent out warnings to doctors.

In November 2004, Biogen Idec and Elan Corporation received approval from the FDA to market and distribute Tysabri (natalizumab). Only four months later, February 2005, the drug was quickly removed from the market after the FDA received several reports of severe illness and death in patients prescribed Tysabri and Avonex. In several cases, the patient or corpse was allegedly diagnosed with Progressive Multifocal Leukoencephalopathy (PML), a rare brain infection that directly affects the central nervous system. Symptoms of PML are similar to a stroke: headaches, memory loss, speech and vision difficulties, limb weakness, and partial paralysis; the disease leads to coma then to death.

To date, approximately 8,000 patients have been involved in clinical trials or prescribed Tysabri for multiple sclerosis, Crohn's disease and rheumatoid arthritis. Biogen Idec and Elan Pharmaceuticals hope to redistribute the drug after extensive evaluations of Tysabri and the possible link to PML.

Biogen merged with IDEC Pharmaceuticals in 2003, creating the billion-dollar company, Biogen Idec, which is based in Cambridge, Massachusetts. Biogen Idec also has another MS drug in the news: the bread-winning drug, Avonex, the most widely prescribed Multiple Sclerosis drug in the world with revenues of $1.4 billion in 2004 has recently been linked to increased risk of liver damage and liver failure.

Greg Jones & Associates is urging patients that have had adverse side effects with the prescription drugs Tysabri or Avonex, to have their case reviewed at www.lawyersandsettlements.com; each case will be evaluated by a lawyer at no charge.

For more details about this product recall and potential class action lawsuit, visit
https://www.lawyersandsettlements.com/case/tysabri

About Online Legal Services Ltd (OLS) and www.lawyersandsettlements.com
OLS is a privately held Internet marketing company that specializes in joint advertising campaigns for lawyers and law firms. Lawyersandsettlements.com offers a comprehensive website with up-to-date information on legal news, class action lawsuits, personal injury cases, settlement details, product recalls, and more. Consumers can complete free case evaluations and subscribe to free newsletters.

Visit us at:
http://www.lawyersandsettlements.com/

Contact us at:
604-608-3435

# # #

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
Tracy Laxdal
WWW.LAWYERSANDSETTLEMENTS.COM
3603034173
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright